相关实验视频

Updated: Sep 9, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

通过调节Sirt1,保护LncRNASirt1-AS免受心脏缩的影响

Xuejiao Wei^1,2, Chenrui Zhang¹, Shuanglong Mou¹

¹Guizhou University Medical College, Guiyang, Guizhou, PR China.

Journal of cardiovascular pharmacology and therapeutics

|August 29, 2025

概括

通过调节Sirt1的表达, Sirtuin- 1抗意义 (Sirt1- AS) 长非编码RNA可以防止心脏缩. 低调Sirt1-AS会恶化心脏缩,这表明它具有治疗潜力.

科学领域:

心血管生物学
分子心脏病学
表观遗传学

背景情况:

长非编码RNAs (lncRNAs) 是心血管疾病的关键调节剂.
Sirtuin-1-antisense (Sirt1-AS) 是一种涉及心血管病理的 lncRNA.
了解 lncRNA 的作用对于新的治疗策略至关重要.

研究的目的:

研究Sirt1-AS在压力过载引起的心脏缩中的作用.
阐明Sirt1-AS功能背后的分子机制.
探索Sirt1-AS作为心脏缩的潜在治疗点.

主要方法:

使用横向大动脉收缩 (TAC) 建立心脏缩的小鼠模型.
在心脏组织和接受 angiotensin II (AngII) 治疗的心肌细胞中评估Sirt1- AS和Sirt1表达.
使用Sirt1-AS过度表达和倒置技术,以及Sirt1抑制,以评估功能影响.

主要成果:

在TAC诱导的心脏缩和AngII治疗心肌细胞中,Sirt1-AS表达显著下调.
过度表达Sirt1- AS减轻了心脏缩,而Sirt1- AS减轻了心脏缩.
发现Sirt1- AS直接调节Sirt1的mRNA和蛋白质水平,其保护作用依赖于Sirt1.

结论:

通过调节Sirt1的表达,Sirt1-AS对心脏缩起着保护作用.
这项研究揭示了一种涉及心脏缩的新机制.
在治疗心脏缩方面,Sirt1-AS是一个有前途的治疗标.

关键词:

美国心肌缩症没有.在Sirt1-AS

更多相关视频

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...